Quick Takeaways
- NSRX - Nasus Pharma Ltd has 8 insiders with reported activity on this page.
- Net insider value flow over the last year: +$41,504.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 8 Insiders of Nasus Pharma Ltd
- Symbol
- NSRX on NYSE
- Location
- Tel Aviv Yafo, Israel
What Changed
- Buy value: $41,504; sell value: $0.
- Net share flow: +17,900.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$41,504.
Buys
$41,504
Shares: 17,900
Insiders: 1
Sells
$0
Shares: 0
Insiders: 0
Net
+$41,504
Shares: +17,900
Insiders: 1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 17,900 | 0 | $41,504 | $0 | +$41,504 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Nasus Pharma Ltd executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Udi Gilboa | Founder & Executive Chairman | $17,609,724 | Mixed | 18 Mar 2026 | ||
| Dalia Megiddo | Chief Development Officer, Director, Founder | $17,331,479 | Mixed | 18 Mar 2026 | ||
| Ronnie Hershman | Director | $12,247,471 | Mixed | 18 Mar 2026 | ||
| Dan Benjamin Teleman | Chief Executive Officer, Director | $590,286 | +$41,504 | +7.6% | Filing P/S | 22 Apr 2026 |
| Silberman David | Director | Mixed | 18 Mar 2026 | |||
| Eyal Rubin | Chief Financial Officer, EVP | Mixed | 18 Mar 2026 | |||
| Sharon Shacham | Director | Mixed | 18 Mar 2026 | |||
| Israel Isaac | Director | Mixed | 18 Mar 2026 |
Top shareholders of Nasus Pharma Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Udi Gilboa |
3/4/5
13D/G
|
Founder & Executive Chairman |
21%
from 13D/G
|
1,924,476
|
$17,609,724 | — | 18 Mar 2026 | |
| Dalia Megiddo |
3/4/5
13D/G
|
Chief Development Officer, Director, Founder · Dr. Dalia Megiddo |
21%
from 13D/G
|
1,894,068
|
$17,331,479 | — | 18 Mar 2026 | |
| Ronnie Hershman |
3/4/5
13D/G
|
Director · Dr. Ronnie Hershman |
15%
from 13D/G
|
1,338,463
|
$12,247,471 | — | 18 Mar 2026 | |
| Funicular Funds, LP |
13D/G
|
— |
5.2%
|
612,913
|
$3,309,730 | $0 | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13D/G
13F
|
Company |
10%
|
1,169,910
|
$2,714,191 | $0 | 31 Mar 2026 | |
| Cable Car Capital, LP |
13F
|
Company |
5.1%
|
601,998
|
$1,336,436 | — | 31 Mar 2026 | |
| Velan Capital Investment Management LP |
13F
|
Company |
3.1%
|
359,390
|
$797,846 | — | 31 Mar 2026 | |
| Dan Benjamin Teleman |
3/4/5
|
Chief Executive Officer, Director |
1.3%
|
156,991
|
$590,286 | +$41,504 | 22 Apr 2026 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
1.2%
|
134,771
|
$299,192 | — | 31 Mar 2026 | |
| Bleichroeder LP |
13F
|
Company |
0.77%
|
89,848
|
$199,463 | — | 31 Mar 2026 | |
| Empery Asset Management, LP |
13F
|
Company |
0.39%
|
45,803
|
$101,683 | — | 31 Mar 2026 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.33%
|
38,897
|
$86,000 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.03%
|
3,094
|
$6,869 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.02%
|
2,000
|
$4,440 | — | 31 Mar 2026 | |
| Capital Point Ltd. |
13D/G
|
— |
6.4%
|
575,129
|
— | $0 | 14 Aug 2025 |
Recent Insider Transactions by Companies or Individuals for Nasus Pharma Ltd
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Dan Benjamin Teleman | NSRX | Ordinary Shares | Purchase | 1.88% | $10,904 | $3.76 | 2,900 | 156,991 | 22 Apr 2026 | Direct |
| Dan Benjamin Teleman | NSRX | Ordinary Shares | Purchase | 240.2% | $30,600 | $2.04 | 15,000 | 21,246 | 31 Mar 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.